Corneal in vivo confocal microscopy to detect belantamab mafodotin-induced ocular toxicity early and adjust the dose accordingly: a case report

BACKGROUND: New targeted antibody–drug conjugates (ADCs) against multiple myeloma are known to induce adverse effects that may lead to treatment discontinuation. Preclinical studies reported early severe ocular damage related to the use of belantamab mafodotin (belamaf), including ocular surface inf...

Descripción completa

Detalles Bibliográficos
Autores principales: Marquant, Kevin, Quinquenel, Anne, Arndt, Carl, Denoyer, Alexandre
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8489063/
https://www.ncbi.nlm.nih.gov/pubmed/34602074
http://dx.doi.org/10.1186/s13045-021-01172-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8489063/
https://www.ncbi.nlm.nih.gov/pubmed/34602074
http://dx.doi.org/10.1186/s13045-021-01172-5

Ejemplares similares